Another “new kid on the block” yet to be approved and incorporated into the guidelines is TAS-102, an oral fluoropyrimidine. Data from the recent RECOURSE study (Refractory Colorectal Cancer Study) showed an overall survival benefit of the novel drug vs. placebo when added to best supportive care after two or more prior regimens for mCRC (Ann. Oncol. 2014;25-4: Abstr. LBA13).
Dr. Van Cutsem has received research funding from Amgen, Bayer, Boehringer, Lilly, Merck, Merck Serono, Novartis, Roche, and Sanofi.